Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.61 |
| ▸ | KDR | P35968 | 5/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.61 |
| ▸ | FLT4 | P35916 | 2/20 | 0.61 |
| ▸ | FBP1 | P09467 | 2/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | INSR | P06213 | 1/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | CLK1 | P49759 | 1/20 | 0.61 |
| ▸ | TEK | Q02763 | 1/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.61 |
| ▸ | CIT | O14578 | 1/20 | 0.57 |
| ▸ | GAK | O14976 | 1/20 | 0.57 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.57 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28384466 | 0.99 | EGFR (0.60) | EGFRKDREPHB4ERBB2FLT4 | |
| SCHEMBL28428839 | 0.94 | KDR (0.52) | EGFRKDREPHB4ERBB2FLT4 | |
| SCHEMBL28424820 | 0.90 | EGFR (0.58) | EGFRKDREPHB4GAKRIPK2 | |
| SCHEMBL28427303 | 0.89 | EGFR (0.60) | EGFRKDRERBB2FBP1ABL1 | |
| SCHEMBL22394455 | 0.85 | EGFR (0.66) | EGFRKDREPHB4ERBB2PDGFRB | |
| SCHEMBL15520010 | 0.81 | ENPP1 (0.50) | EGFRKDREPHB4ERBB2MAPT | |
| SCHEMBL15519473 | 0.79 | HDAC1 (0.61) | EGFRKDRAURKAAURKBLCK | |
| SCHEMBL15520192 | 0.79 | HDAC1 (0.63) | EGFRKDRAURKAAURKBLCK | |
| SCHEMBL13189303 | 0.79 | EGFR (0.70) | EGFRKDREPHB4ERBB2FLT4 | |
| SCHEMBL30505605 | 0.78 | EGFR (1.00) | EGFRKDREPHB4ERBB2FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258344-B2 | Azaaromatic amide derivatives for the treatment of cancer | SHENZHEN FORWARD PHARMACEUTICALS CO., LTD. (CN) | 2025-03-25 | — | — | US | disclosed |
| CN-117327059-A | Compounds that inhibit and induce protein degradation | 北京泰德制药股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-117222435-A | HER 2-targeted Fc antigen binding fragment-drug conjugates | 默克专利有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-113912589-B | Compounds that inhibit and induce protein degradation | 北京泰德制药股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-3705478-B1 | TRIAZINE COMPOUND AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | SHENZHEN FORWARD PHARMACEUTICALS CO LTD (CN) | 2023-10-04 | — | — | EP | disclosed |
| CN-114829364-B | Compounds that inhibit and induce degradation of EGFR kinase | 北京泰德制药股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116507337-A | ATR inhibitors and uses thereof | 上海德琪医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116462685-A | Heterocyclic compound, pharmaceutical composition containing same and antitumor application of heterocyclic compound | 和径医药科技（上海）有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116082457-A | Protein compounds and uses thereof | 堪培拉大学 | 2023-05-09 | — | — | CN | disclosed |
| CN-109843858-B | Certain chemical entities, compositions and methods | 润新生物公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20220177473-A1 | AZAAROMATIC AMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | SHENZHEN FORWARD PHARMACEUTICALS CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| EP-3950686-A1 | N-HETEROAROMATIC AMIDE DERIVATIVES FOR TREATMENT OF CANCER | Shenzhen Forward Pharmaceuticals Co., Ltd. (CN) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021121261-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | 北京泰德制药股份有限公司 | 2021-06-24 | — | — | WO | disclosed |
| WO-2021036922-A1 | COMPOUND INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK | 北京泰德制药股份有限公司 | 2021-03-04 | — | — | WO | disclosed |
| EP-3705478-A1 | TRIAZINE COMPOUND AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Shenzhen Forward Pharmaceuticals Co., Ltd. (CN) | 2020-09-09 | — | — | EP | disclosed |
| CN-107098863-B | Preparation method of gefitinib | 重庆莱美隆宇药业有限公司 | 2020-04-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177473-A1 | AZAAROMATIC AMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | ERBB4, EGFR, ERBB2 | EGFR 2/4885KDR 27/4885EPHB4 125/4885 |
| US-12258344-B2 | Azaaromatic amide derivatives for the treatment of cancer | ERBB4, EGFR, ERBB2 | EGFR 2/4885KDR 27/4885EPHB4 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.